Details
Stereochemistry | ACHIRAL |
Molecular Formula | C20H17F3N2O4 |
Molecular Weight | 406.3552 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=C2C(=CC=C1)N(C)C(=O)C(C(=O)N(C)C3=CC=C(C=C3)C(F)(F)F)=C2O
InChI
InChIKey=ONDYALNGTUAJDX-UHFFFAOYSA-N
InChI=1S/C20H17F3N2O4/c1-24(12-9-7-11(8-10-12)20(21,22)23)18(27)16-17(26)15-13(25(2)19(16)28)5-4-6-14(15)29-3/h4-10,26H,1-3H3
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P06702 Gene ID: 6280.0 Gene Symbol: S100A9 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/27298414 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
0.26 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19755981/ |
0.5 mg 1 times / day steady-state, oral dose: 0.5 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
TASQUINIMOD plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
4.8 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19755981/ |
0.5 mg 1 times / day steady-state, oral dose: 0.5 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
TASQUINIMOD plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
40 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19755981/ |
0.5 mg 1 times / day steady-state, oral dose: 0.5 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
TASQUINIMOD plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT01234311
Tasquinimod is given orally at a dose of 1 mg once daily.
Route of Administration:
Oral
LNCaP prostate tumor cells were cultured with 50 uM of tasquinimod for 24 h to test its effect on gene expression. At 10 uM tasquinimod the TSP1 mRNA expression was elevated at 6 h and peaked after 72 h. Moreover, after 72 h exposure the TSP1 mRNA levels was already elevated at a dose of 1 uM tasquinimod.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C1742
Created by
admin on Fri Dec 15 16:14:11 GMT 2023 , Edited by admin on Fri Dec 15 16:14:11 GMT 2023
|
||
|
FDA ORPHAN DRUG |
561916
Created by
admin on Fri Dec 15 16:14:11 GMT 2023 , Edited by admin on Fri Dec 15 16:14:11 GMT 2023
|
||
|
NCI_THESAURUS |
C129820
Created by
admin on Fri Dec 15 16:14:11 GMT 2023 , Edited by admin on Fri Dec 15 16:14:11 GMT 2023
|
||
|
FDA ORPHAN DRUG |
877022
Created by
admin on Fri Dec 15 16:14:11 GMT 2023 , Edited by admin on Fri Dec 15 16:14:11 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
100000139620
Created by
admin on Fri Dec 15 16:14:11 GMT 2023 , Edited by admin on Fri Dec 15 16:14:11 GMT 2023
|
PRIMARY | |||
|
C74080
Created by
admin on Fri Dec 15 16:14:11 GMT 2023 , Edited by admin on Fri Dec 15 16:14:11 GMT 2023
|
PRIMARY | |||
|
756U07KN1R
Created by
admin on Fri Dec 15 16:14:11 GMT 2023 , Edited by admin on Fri Dec 15 16:14:11 GMT 2023
|
PRIMARY | |||
|
254964-60-8
Created by
admin on Fri Dec 15 16:14:11 GMT 2023 , Edited by admin on Fri Dec 15 16:14:11 GMT 2023
|
PRIMARY | |||
|
8538
Created by
admin on Fri Dec 15 16:14:11 GMT 2023 , Edited by admin on Fri Dec 15 16:14:11 GMT 2023
|
PRIMARY | |||
|
TASQUINIMOD
Created by
admin on Fri Dec 15 16:14:11 GMT 2023 , Edited by admin on Fri Dec 15 16:14:11 GMT 2023
|
PRIMARY | |||
|
DTXSID90180183
Created by
admin on Fri Dec 15 16:14:11 GMT 2023 , Edited by admin on Fri Dec 15 16:14:11 GMT 2023
|
PRIMARY | |||
|
54682876
Created by
admin on Fri Dec 15 16:14:11 GMT 2023 , Edited by admin on Fri Dec 15 16:14:11 GMT 2023
|
PRIMARY | |||
|
DB05861
Created by
admin on Fri Dec 15 16:14:11 GMT 2023 , Edited by admin on Fri Dec 15 16:14:11 GMT 2023
|
PRIMARY | |||
|
SUB88412
Created by
admin on Fri Dec 15 16:14:11 GMT 2023 , Edited by admin on Fri Dec 15 16:14:11 GMT 2023
|
PRIMARY | |||
|
C516109
Created by
admin on Fri Dec 15 16:14:11 GMT 2023 , Edited by admin on Fri Dec 15 16:14:11 GMT 2023
|
PRIMARY | |||
|
CHEMBL2107784
Created by
admin on Fri Dec 15 16:14:11 GMT 2023 , Edited by admin on Fri Dec 15 16:14:11 GMT 2023
|
PRIMARY | |||
|
m10480
Created by
admin on Fri Dec 15 16:14:11 GMT 2023 , Edited by admin on Fri Dec 15 16:14:11 GMT 2023
|
PRIMARY | Merck Index |
ACTIVE MOIETY